Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease

Samiksha Nayak, Archana Sridhara, Rita Melo, Luciana Richer, Natalie H. Chee, Jiyoon Kim, Vincent Linder, David Steinmiller, Samuel K. Sia, Maria Gomes-Solecki

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Currently, diagnostic testing for Lyme disease is done by determination of the serologic responses to Borrelia burgdorferi antigens, with the exception of the early localized phase of disease where diagnosis must be done clinically. Here, we describe the use of microfluidics technology to develop a multiplexed rapid lab-on-a-chip point of care (POC) assay for the serologic diagnosis of human Lyme disease. Following ELISA screening of 12 candidate antigens, we tested 8 on a microfluidic diagnostic system, called mChip-Ld, using a set of 60 serological samples. The mChip-Ld test, which can be performed in 15 minutes at the point of care, showed promising performance for detection of antibodies to B. burgdorferi using the PPO triplex test (rP100 + PepVF + rOspC-K, AUC of 0.844) compared to a gold-standard reference of culture confirmed clinical samples. The performance is comparable to the commonly used C6 peptide by lab-based ELISA. In addition, the mChip-Ld test showed promising performance for early-stage diagnosis of the disease using the antigen OspC-K (sensitivity and specificity of 84% and 92%, respectively; AUC of 0.877). Overall, this study underscores the potential of using microfluidics to aid the diagnosis of Lyme disease at the point of care.

Original languageEnglish (US)
Article number35069
JournalScientific Reports
Volume6
DOIs
StatePublished - Oct 11 2016

Fingerprint

Point-of-Care Systems
Microfluidics
Lyme Disease
Serologic Tests
Borrelia burgdorferi
Area Under Curve
Enzyme-Linked Immunosorbent Assay
Antigens
Gold
Early Diagnosis
Technology
Sensitivity and Specificity
Peptides
Antibodies

All Science Journal Classification (ASJC) codes

  • General

Cite this

Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease. / Nayak, Samiksha; Sridhara, Archana; Melo, Rita; Richer, Luciana; Chee, Natalie H.; Kim, Jiyoon; Linder, Vincent; Steinmiller, David; Sia, Samuel K.; Gomes-Solecki, Maria.

In: Scientific Reports, Vol. 6, 35069, 11.10.2016.

Research output: Contribution to journalArticle

Nayak, S, Sridhara, A, Melo, R, Richer, L, Chee, NH, Kim, J, Linder, V, Steinmiller, D, Sia, SK & Gomes-Solecki, M 2016, 'Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease', Scientific Reports, vol. 6, 35069. https://doi.org/10.1038/srep35069
Nayak S, Sridhara A, Melo R, Richer L, Chee NH, Kim J et al. Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease. Scientific Reports. 2016 Oct 11;6. 35069. https://doi.org/10.1038/srep35069
Nayak, Samiksha ; Sridhara, Archana ; Melo, Rita ; Richer, Luciana ; Chee, Natalie H. ; Kim, Jiyoon ; Linder, Vincent ; Steinmiller, David ; Sia, Samuel K. ; Gomes-Solecki, Maria. / Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease. In: Scientific Reports. 2016 ; Vol. 6.
@article{431c111ea21b43509a198a511ddaec7a,
title = "Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease",
abstract = "Currently, diagnostic testing for Lyme disease is done by determination of the serologic responses to Borrelia burgdorferi antigens, with the exception of the early localized phase of disease where diagnosis must be done clinically. Here, we describe the use of microfluidics technology to develop a multiplexed rapid lab-on-a-chip point of care (POC) assay for the serologic diagnosis of human Lyme disease. Following ELISA screening of 12 candidate antigens, we tested 8 on a microfluidic diagnostic system, called mChip-Ld, using a set of 60 serological samples. The mChip-Ld test, which can be performed in 15 minutes at the point of care, showed promising performance for detection of antibodies to B. burgdorferi using the PPO triplex test (rP100 + PepVF + rOspC-K, AUC of 0.844) compared to a gold-standard reference of culture confirmed clinical samples. The performance is comparable to the commonly used C6 peptide by lab-based ELISA. In addition, the mChip-Ld test showed promising performance for early-stage diagnosis of the disease using the antigen OspC-K (sensitivity and specificity of 84{\%} and 92{\%}, respectively; AUC of 0.877). Overall, this study underscores the potential of using microfluidics to aid the diagnosis of Lyme disease at the point of care.",
author = "Samiksha Nayak and Archana Sridhara and Rita Melo and Luciana Richer and Chee, {Natalie H.} and Jiyoon Kim and Vincent Linder and David Steinmiller and Sia, {Samuel K.} and Maria Gomes-Solecki",
year = "2016",
month = "10",
day = "11",
doi = "10.1038/srep35069",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease

AU - Nayak, Samiksha

AU - Sridhara, Archana

AU - Melo, Rita

AU - Richer, Luciana

AU - Chee, Natalie H.

AU - Kim, Jiyoon

AU - Linder, Vincent

AU - Steinmiller, David

AU - Sia, Samuel K.

AU - Gomes-Solecki, Maria

PY - 2016/10/11

Y1 - 2016/10/11

N2 - Currently, diagnostic testing for Lyme disease is done by determination of the serologic responses to Borrelia burgdorferi antigens, with the exception of the early localized phase of disease where diagnosis must be done clinically. Here, we describe the use of microfluidics technology to develop a multiplexed rapid lab-on-a-chip point of care (POC) assay for the serologic diagnosis of human Lyme disease. Following ELISA screening of 12 candidate antigens, we tested 8 on a microfluidic diagnostic system, called mChip-Ld, using a set of 60 serological samples. The mChip-Ld test, which can be performed in 15 minutes at the point of care, showed promising performance for detection of antibodies to B. burgdorferi using the PPO triplex test (rP100 + PepVF + rOspC-K, AUC of 0.844) compared to a gold-standard reference of culture confirmed clinical samples. The performance is comparable to the commonly used C6 peptide by lab-based ELISA. In addition, the mChip-Ld test showed promising performance for early-stage diagnosis of the disease using the antigen OspC-K (sensitivity and specificity of 84% and 92%, respectively; AUC of 0.877). Overall, this study underscores the potential of using microfluidics to aid the diagnosis of Lyme disease at the point of care.

AB - Currently, diagnostic testing for Lyme disease is done by determination of the serologic responses to Borrelia burgdorferi antigens, with the exception of the early localized phase of disease where diagnosis must be done clinically. Here, we describe the use of microfluidics technology to develop a multiplexed rapid lab-on-a-chip point of care (POC) assay for the serologic diagnosis of human Lyme disease. Following ELISA screening of 12 candidate antigens, we tested 8 on a microfluidic diagnostic system, called mChip-Ld, using a set of 60 serological samples. The mChip-Ld test, which can be performed in 15 minutes at the point of care, showed promising performance for detection of antibodies to B. burgdorferi using the PPO triplex test (rP100 + PepVF + rOspC-K, AUC of 0.844) compared to a gold-standard reference of culture confirmed clinical samples. The performance is comparable to the commonly used C6 peptide by lab-based ELISA. In addition, the mChip-Ld test showed promising performance for early-stage diagnosis of the disease using the antigen OspC-K (sensitivity and specificity of 84% and 92%, respectively; AUC of 0.877). Overall, this study underscores the potential of using microfluidics to aid the diagnosis of Lyme disease at the point of care.

UR - http://www.scopus.com/inward/record.url?scp=84991461047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991461047&partnerID=8YFLogxK

U2 - 10.1038/srep35069

DO - 10.1038/srep35069

M3 - Article

C2 - 27725740

AN - SCOPUS:84991461047

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 35069

ER -